The Ovarian Cancer Research Fund
The Ovarian Cancer Research Fund (OCRF) is a 501(c) 3 not-for-profit organization devoted to the formulation of early diagnostic treatment programs and research towards the ultimate conquest of ovarian cancer.
As OCRF strives to find an early diagnostic tool and a cure, it also seeks to support patients and their loved ones in understanding this disease and its treatment as well as to provide outreach programs and raise public awareness.
OCRF was founded in December 1994 by Sol Schreiber to honor the memory of his wife Ann, a distinguished public administrator, and her courageous five-year battle with ovarian cancer. Under the leadership of Liz Tilberis, the beloved late editor-in-chief of Harper’s Bazaar, OCRF experienced tremendous growth and gained national prominence as an organization committed to changing the course of this deadly disease. Drawing on her numerous contacts, Liz helped unite the worlds of fashion, beauty, and entertainment around this important cause.
Today, thanks to the ongoing commitment of these industries and the support of countless individuals, OCRF is one of the leading independent agencies dedicated to advancing ovarian cancer research in the United States.
Ovarian cancer is the leading cause of death of all gynecologic cancers in the United States. In 2005, it was estimated that roughly 22,220 women would be diagnosed with this form of cancer and close to 16,210 would lose their lives to it. Ovarian cancer is an insidious disease that often strikes without warning and without cause.
Currently there is no effective means of early detection. As a result, just over half of all patients are alive and disease free five years after diagnosis. However, if detected and treated early, the five-year survival rate is 95%.
Every day OCRF makes a difference in thousands of women’s lives and the lives of their families. With each new research grant awarded, new steps are being taken toward finding a cure. Currently there is no effective means of early detection.
Since 1998, through its distinguished Scientific Advisory Committee, OCRF has funded 63 of the brightest women and men in the field today at 28 leading medical centers across the country. Using the latest technologies, these investigators are breaking new ground though the discoveries of new treatment modalities, genetic markers, and diagnostic tools. Together, these researchers have achieved remarkable results and have received unparalleled training opportunities that will greatly impact the field of ovarian cancer research as a whole.